Con­gress takes an­oth­er look at re­clas­si­fy­ing psilo­cy­bin and MD­MA

Months af­ter Sens. Cory Book­er (D-NJ) and Rand Paul (R-KY) in­tro­duced a bill that would ex­pand ac­cess to Sched­ule I drugs for ter­mi­nal­ly ill pa­tients, the law­mak­ers are tak­ing an­oth­er stab.

Book­er and Paul on Thurs­day in­tro­duced a new bill called the Break­through Ther­a­pies Act, which would al­low the Drug En­force­ment Ad­min­is­tra­tion to make the nec­es­sary find­ings to re­clas­si­fy break­through ther­a­pies such as MD­MA or psilo­cy­bin as Sched­ule II drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER